Diego Araiza-Garaygordobil, Unidad Coronaria y Urgencias Cardiovasculares, Instituto Nacional de Cardiología Ignacio Chávez, Ciudad de México, México
Carla A. Berrio-Becerra, Unidad Coronaria y Urgencias Cardiovasculares, Instituto Nacional de Cardiología Ignacio Chávez, Ciudad de México, México
Emmanuel Tapia, Department of Rheumatology, Instituto Nacional de Cardiología Ignacio Chávez, Mexico City, Mexico
Miranda Montes, Department of Dermatology, Hospital General de México, Mexico City, Mexico
Mayra R. Báez-Aguirre, Department of Dermatology, Centro Dermatológico de Sinaloa Dr. Jesús Rodolfo Acedo Cárdenas, Culiacán, Sin., Mexico
Columba Navarro-Romero, Department of Rheumatology, General Area, Hospital #4, Instituto Mexicano del Seguro Social (IMSS), Guadalupe, N.L., Mexico
Ana Álvarez del Castillo-Araujo, Private Practice, Reumatología Integral, Monterrey, N.L., Mexico
Sandra Chris-Rincón, Department of Rheumatology, Regional Hospital Monterrey, Instituto de Seguridad y Servicios Sociales de los Trabajadores del Estado (ISSSTE), Monterrey, N.L., Mexico
Jimena González-Salido, Coronary Care Unit and Department of Cardiovascular Emergency, Instituto Nacional de Cardiología Ignacio Chávez, Mexico City, Mexico
Sarai Hernández-Pastrana, Section of Critical Care In Cardiology, Division of Cardiology, University of California, San Francisco, CA, USA
Psoriatic disease (PD) and spondyloarthritis (SpA) are associated with increased risk of atherosclerotic cardiovascular disease, mainly due to chronic low-grade inflammation, endothelial dysfunction, and metabolic alterations. However, cardiovascular risk in these patients is often underestimated by traditional assessment tools. To analyze and summarize the evidence on the association between PD, SpA, and cardiovascular disease, and to assess strategies for improving their clinical identification and management. A narrative review including observational studies, clinical trials, previous reviews, and expert opinion from a multidisciplinary panel. Patients with PD and SpA show a higher incidence of acute myocardial infarction and cerebrovascular disease. Persistent inflammation and metabolic disturbances contribute significantly to this underestimated risk. Cardiovascular risk assessment should be more accurate and tailored. Targeted anti-inflammatory strategies and early risk identification may improve outcomes and reduce cardiovascular morbidity and mortality in this population.
Keywords: scular risk. Psoriatic disease. Spondyloarthritis. Inflammation. Endothelial dysfunction.
